Trial details

Trial short name: SS23LC

Official title: A phase I/II trial of stereotactic body radiation therapy (SBRT) for selected stage II or III non-small cell lung cancer (NSCLC) patients ineligible for surgery or radical chemoradiation

Principal Investigator: Dr. May Tsao

Cancer type: Lung
Cancer location: Lung
Disease stage: Early Cancer
Trial phase: Phase 1, Phase 2
Intervention:

Registration #:

Contact e-mail: cancerclinicaltrials@sunnybrook.ca

Trial description:
To evaluate the safety of thoracic SBRT for selected stage II and III NSCLC patients who are ineligible for surgery and ineligible for concurrent chemoradiation.

Inclusion criteria • American Joint Commission on Cancer (AJCC 8th edition) stage II or III NSCLC • Inoperable Stage II or III NSCLC deemed ineligible for concurrent radical chemoradiation • Planned systemic treatment (chemotherapy, immunotherapy, targeted agents) is permissible at the discretion of the treating medical oncologist – see section 5 for details. • Age 18 years or older • Willingness and ability to provide informed consent • Life expectancy more than 3 months • ECOG ≤ 3 Exclusion criteria • Prior thoracic radiation • Interstitial lung disease • scleroderma • Pregnancy or lactating women • Inability to attend the full course of SBRT or planned follow-up visits • Concurrent or planned lung cancer targeted therapy • Active concurrent malignancy (EXCEPT concurrent superficial bladder cancer, in situ cancer or any non-melanoma localized skin cancers- these exceptions are eligible for this trial)